Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Int J Nanomedicine. 2016 Oct 31:11:5645-5669. doi: 10.2147/IJN.S115727. eCollection 2016.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years. The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency. This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.

Keywords: drug delivery system; hepatocellular carcinoma; ligand; nanoparticle; targeted therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / metabolism
  • Humans
  • Ligands
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Molecular Targeted Therapy / methods*

Substances

  • Antineoplastic Agents
  • Ligands